From: Genetic and immunological biomarkers predict metastatic disease recurrence in stage III colon cancer
 | All patients | Occurrence of metastasis |  | |||
---|---|---|---|---|---|---|
n = 84 | (100%) | Metachr. Metastasis (n = 37) | Metachr. Metastasis (44%) | p (metachr. Met.) | ||
Sex | Male | 54 | (64) | 25 | (46) | 0.578 |
Female | 30 | (36) | 12 | (40) | ||
Age (years, median) |  | 67 (range 35–86) | 37 | (44) | 0.428 | |
Period of enrollment | before 1993 | 42 | (50) | 22 | (52) | 0.124 |
1994 and after | 42 | (50) | 15 | (36) | ||
Sidedness | Right colon | 35 | (42) | 17 | (49) | 0.633 |
Left colon | 44 | (52) | 19 | (43) | ||
Unknown | 5 | (6) | 1 | (20) | ||
Histology | Adenocarcinoma | 75 | (89) | 34 | (46) | 0.076 |
Mucinous adenocarcinoma | 7 | (9) | 1 | (14) | ||
Signet ring cell | 2 | 7 (2) | 2 | (100) | ||
Grading | Low (G1–2) | 48 | (57) | 18 | (38) | 0.163 |
High (G3–4) | 36 | (43) | 19 | (53) | ||
pT | T1 | 0 | (0) | 0 | (0) | 0.054 |
T2 | 6 | (7) | 4 | (67) | ||
T3 | 57 | (68) | 20 | (35) | ||
T4 | 21 | (25) | 13 | (62) | ||
pN | N1 | 58 | (69) | 19 | (33) | 0.002a |
N2 | 26 | (31) | 18 | (69) | ||
Lymphatic invasion | L0 | 57 | (68) | 25 | (44) | 0.960 |
L+ | 27 | (32) | 12 | (44) | ||
Angioinvasion | V0 | 79 | (94) | 34 | (43) | 0.459 |
V+ | 5 | (6) | 3 | (60) | ||
Adjuvant chemotherapy | None | 41 | (49) | 16 | (39) | 0.500 |
5-FU alone | 27 | (32) | 12 | (44) | ||
other | 16 | (19) | 9 | (56) | ||
Alive status | Alive | 31 | (37) | 2 | (6) | < 0.001 |
Tumour rel. Death | 33 | (39) | 33 | (100) | ||
Non-tumour rel. Death | 20 | (24) | 2 | (10) | ||
Occurrence of met. | No metastases | 47 | (56) | 0 | (0) | – |
Metachronous metastasis | 37 | (44) | 37 | (100) |